35 related articles for article (PubMed ID: 15493358)
1. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
Balar AV; Apolo AB; Ostrovnaya I; Mironov S; Iasonos A; Trout A; Regazzi AM; Garcia-Grossman IR; Gallagher DJ; Milowsky MI; Bajorin DF
J Clin Oncol; 2013 Feb; 31(6):724-30. PubMed ID: 23341513
[TBL] [Abstract][Full Text] [Related]
2. Outcomes with chemotherapy in carcinoma penis: Experience from a tertiary cancer center.
Mailankody S; Radhakrishnan V; Raja A; Ganesan TS; Dhanushkodi M; Sagar TG
Indian J Cancer; 2023; 60(3):396-402. PubMed ID: 36861700
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.
Mooney CJ; Nagaiah G; Fu P; Wasman JK; Cooney MM; Savvides PS; Bokar JA; Dowlati A; Wang D; Agarwala SS; Flick SM; Hartman PH; Ortiz JD; Lavertu PN; Remick SC
Thyroid; 2009 Mar; 19(3):233-40. PubMed ID: 19265494
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.
Médioni J; Di Palma M; Guillot A; Spaeth D; Théodore C
BMC Cancer; 2016 Mar; 16():217. PubMed ID: 26975779
[TBL] [Abstract][Full Text] [Related]
5. Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study.
Dai MS; Chao TC; Chiu CF; Lu YS; Shiah HS; Jackson CGCA; Hung N; Zhi J; Cutler DL; Kwan R; Kramer D; Chan WK; Qin A; Tseng KC; Hung CT; Chao TY
Ther Adv Med Oncol; 2023; 15():17588359231183680. PubMed ID: 37492633
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.
Bui N; Kamat N; Ravi V; Chawla S; Lohman M; Ganjoo KN
Rare Tumors; 2018; 10():2036361318771771. PubMed ID: 29760870
[TBL] [Abstract][Full Text] [Related]
7. Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models.
Guo Y; Zeng H; Chang X; Wang C; Cui H
BMC Cancer; 2018 Jan; 18(1):81. PubMed ID: 29338697
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates.
Ashdown ML; Robinson AP; Yatomi-Clarke SL; Ashdown ML; Allison A; Abbott D; Markovic SN; Coventry BJ
F1000Res; 2015; 4():232. PubMed ID: 26834979
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for bladder cancer in patients with impaired renal function.
Nicholson S
Nat Rev Urol; 2011 Nov; 9(1):52-7. PubMed ID: 22105318
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
[TBL] [Abstract][Full Text] [Related]
11. [Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy].
Ito H; Aoki Y; Oyama N; Miwa Y; Akino H; Yokoyama O
Gan To Kagaku Ryoho; 2011 Mar; 38(3):481-4. PubMed ID: 21403460
[TBL] [Abstract][Full Text] [Related]
12. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
Friedland DM; Dakhil S; Hollen C; Gregurich MA; Asmar L
Cancer Invest; 2004; 22(3):374-82. PubMed ID: 15493358
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
14. Salvage treatment with low-dose weekly paclitaxel in elderly or poor performance status patients with metastatic urothelial carcinoma.
Han JJ; Kim YJ; Kim JW; Chang H; Lee JO; Lee KW; Jeong CW; Kim JH; Hong SK; Bang SM; Byun SS; Lee SE; Lee JS
Tumori; 2014; 100(4):439-45. PubMed ID: 25296594
[TBL] [Abstract][Full Text] [Related]
15. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
Ruiz M; Salvador J; Bayo J; Lomas M; Moreno A; Valero M; Bernabé R; Vicente D; Jiménez J; Lopez-Ladrón A
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1085-90. PubMed ID: 18365200
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
